What is Mounjaro?

Mounjaro is an innovative prescription medication that has recently garnered attention for its effectiveness in promoting weight loss. Also known as tirzepatide, Mounjaro was initially developed by pharmaceutical company Eli Lilly as a treatment for individuals with type 2 diabetes. However, groundbreaking trials have demonstrated its remarkable impact on weight management, making it a potential game-changer in the field of obesity treatment.

How Does Mounjaro Work?

Mounjaro has two incretin hormones and it is classified as a ‘dual-agonist’.  This double agonist approach seems to cause people who use Mounjaro weekly injections to lose even more weight than those who use a single-agonist medication.  These receptors stimulate hormones that control blood sugar levels and reduce appetite, triggering weight loss.  The receptors are known as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Bodyline is at the forefront of providing the latest obesity treatment options, as we continue to offer safe, effective, and sustainable medical weight loss programmes.

Administered through a weekly injection, Mounjaro would lead to weight loss as it curbs hunger and reduces caloric intake, thus allowing the user to burn through excess fat stores. It promotes feelings of fullness and satiety, helping individuals adhere to a reduced-calorie diet and achieve sustainable weight loss.

The Promising Results of Mounjaro Trials

Clinical trials have shown promising results for Mounjaro in terms of weight loss and blood sugar control. In a meta-analysis of 22 trials, researchers compared Mounjaro with another GLP-1 receptor agonist called semaglutide (marketed as Ozempic and WeGovy). The findings revealed that tirzepatide (Mounjaro) was superior to semaglutide in controlling blood sugar levels and promoting weight loss.

According to the study, individuals taking Mounjaro experienced greater weight loss compared to those on semaglutide. For instance, the trial results indicated that, on average, a weekly dose of 15mg of Mounjaro resulted in 12lbs more weight loss than the maximum dose of 2.4mg of semaglutide. 

Even lower doses of tirzepatide saw higher levels of weight loss; 10mg of Mounjaro led to a loss of almost 8lbs more than 2.4mg of semaglutide, and 5mg of Mounjaro resulted in a loss of almost 4 more pounds than 1mg semaglutide. 

Contact Bodyline today to find out more about our safe and effective weight loss programmes and range of treatment options.

"*" indicates required fields

By submitting this form you agree to the Bodyline privacy policy.
This field is for validation purposes and should be left unchanged.

Is Mounjaro an Obesity Treatment?

As of November 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the treatment Mounjaro (tirzepatide) for weight loss and weight management in adults aged 18 and over.   

It will be available to be prescribed to those with a BMI of 30 or more, being classed as obese, as well as those with a BMI above 27, therefore overweight, who also have weight-related health problems. These health problems would include prediabetes, high blood pressure, high cholesterol, or heart problems.  

At Bodyline, we are committed to providing the latest and most effective medical weight loss treatments. As pioneers in the field, we offer comprehensive weight loss programs that incorporate different bespoke medical options as part of a holistic approach to weight management. Our experienced weight health clinicians ensure that individuals receive personalized guidance and support throughout their weight loss journey.

Find out more about the other medical weight loss treatment plans we offer.

The Importance of Medical Supervision

It is important to note that Mounjaro, like any prescription medication, should only be used under proper medical supervision. Weight loss medications are most effective when integrated into a fully supported program that includes a reduced-calorie diet, increased physical activity, and lifestyle modifications.

At Bodyline, we take a comprehensive approach to weight loss, considering each individual’s unique needs and goals. Our clinicians thoroughly assess medical history, current medications, and underlying health conditions to determine the most suitable weight loss medication, whether it be tirzepatide or another option. We provide ongoing monitoring and support to ensure the safety and effectiveness of the treatment.

The Journey to Successful Weight Loss

Weight loss is a journey that requires dedication and a multi-faceted approach. While Mounjaro could be a valuable tool in achieving weight loss goals, it is essential to prioritise healthy eating, regular physical activity, and lifestyle modifications into the overall plan. Medical weight loss injections like Mounjaro or WeGovy are there when diet and exercise alone are not producing the results you need. 

If you are interested in exploring weight loss injections like Mounjaro as a potential solution for your weight management, Bodyline is here to help. Our experienced healthcare professionals can provide the guidance and support you need to embark on a successful weight loss journey. Contact us today at 0800 995 6036 or fill out our online contact form for a call back.

Remember, successful weight loss is within reach, and with the right support and tools, you can achieve your goals and improve your overall well-being.

Related blog posts

By now we should all have heard of the incredible weight loss results from GLP-1 receptor agonist medications and their ever-growing popularity. All over the UK, people are searching for access to ‘game changing’ medications to solve their weight problems. Searches for semaglutide, tirzepatide and liraglutide (brand names WeGovy/Ozempic, Mounjaro, and Saxenda respectively) have increased dramatically in the past year, and interest continues to rise. That’s because for the first time ever, there seems to be a potential long-term solution to the obesity epidemic that has afflicted the world over the past 30 years.
If you're on a weight loss journey and are prescribed medication to aid in this process, it's essential to manage your medication intake effectively during Ramadan to ensure both your health and adherence to religious obligations.
Despite the enormous popularity of WeGovy and its incredible impact on weight loss, a shortage of the injectable weight loss therapy has been ongoing in recent months. The semaglutide-containing injection has been dubbed “game-changing” for the treatment of obesity, and demand has been high, but manufacturer Novo Nordisk has struggled to keep up and has only released limited stock.


Contact Bodyline to find out more how we can treat and support you to improve your health and wellbeing.

"*" indicates required fields

Select the Bodyline treatment that you would like to discuss*
By submitting this form you agree to the Bodyline privacy policy.